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Abstract
The oxygenation status of tumors derived from wild-
type C6 glioma cells and clone D27 cells overexpress-
ing dimethylarginine dimethylaminohydrolase (DDAH)
was assessed in vivo using a variety of direct and
indirect assays of hypoxia. Clone D27 tumors exhibit a
more aggressive and better-vascularized phenotype
compared to wild-type C6 gliomas. Immunohisto-
chemical analyses using the 2-nitroimidazole hypoxia
marker pimonidazole, fiber optic OxyLite measure-
ments of tumor pO2, and localized
31P magnetic res-
onance spectroscopy measurements of tumor
bioenergetic status and pH clearly demonstrated that
the D27 tumors were more hypoxic compared to C6
wild type. In the tumor extracts, only glucose concen-
trations were significantly lower in the D27 tumors.
Elevated Glut-1 expression, a reliable functional
marker for hypoxia-inducible factor-1–mediated meta-
bolic adaptation, was observed in the D27 tumors.
Together, the data show that overexpression of DDAH
results in C6 gliomas that are more hypoxic compared
to wild-type tumors, and point strongly to an inverse
relationship of tumor oxygenation and angiogenesis
in vivo—a concept now being supported by the
enhanced understanding of oxygen sensing at the
molecular level.
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Introduction
It is well established that the characteristically chaotic and
poorly regulated blood supply of tumors results in hypoxia,
and that regions of hypoxia in tumors are resistant to both
radiotherapy and chemotherapy [1]. The induction of tumor
hypoxia has often been intuitively linked to the inability of the
tumor vascular network to provide a nutritive blood supply to
the rapidly proliferating tissue [2]. Highly angiogenic tumors
should thus be well oxygenated and responsive to both
radiotherapy and chemotherapy. However, more recent
clinical evidence suggests that sustained tumor hypoxia is
associated with cellular changes, resulting in a more malignant
phenotype. For example, correlates of high vascular density
with necrosis [3] and poor radiotherapeutic [4,5] or chemother-
apeutic [6,7] response have been shown, and tumor hypoxia
has been associated with poor prognosis and the likelihood of
metastasis [8–13]. Taken together, these data suggest that,
paradoxically, tumor hypoxia correlates with high vascular
density in vivo [13]. The most obvious explanation would be
that tumor hypoxia induces angiogenesis so effectively that
hypoxic tumor tissues are often more angiogenic than oxic
tissues. Indeed, hypoxia is a strong stimulus for angiogenesis
in numerous pathologic disorders such as wound healing,
atherogenesis, and retinopathies [14].
There is currently great interest in the relationship of tumor
hypoxia to tumor angiogenesis, and this is being facilitated by
the enhanced understanding of the cellular hypoxia response
at the molecular level [14,15]. In particular, hypoxia-inducible
factor-1 (HIF-1), which is upregulated by low levels of pO2,
activates the transcription of numerous genes whose protein
products facilitate adaptation to hypoxia, driving the tumor
toward a more malignant phenotype. These include genes
encoding glucose transporters, enzymes involved in glycolysis,
and angiogenic growth factors such as vascular endothelial
growth factor (VEGF) [16,17]. This response is also important
in the context of anti–angiogenic strategies designed to treat
highly angiogenic tumors.
Nitric oxide (NO) is another important signalling molecule
and regulator of angiogenesis [18]. Positive correlations be-
tween nitric oxide synthase (NOS) expression and human
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tumor grade have been demonstrated [19–23]. Intracellular
factors that regulate NO synthesis may therefore represent
important targets in the control of tumor progression. We
have recently shown that C6 glioma cells genetically engi-
neered to constitutively overexpress the enzyme dimethyl-
arginine dimethylaminohydrolase (DDAH) result in tumors
that grow twice as fast as the wild type [24]. DDAH metab-
olizes two competitive inhibitors of NO synthesis: asymmet-
ric dimethylarginine (ADMA) and N-monomethyl-L-arginine
(L-NMMA), indirectly leading to an increase in NO levels both
in vitro and in vivo [25]. 1H magnetic resonance imaging
(MRI) studies demonstrated that tumors derived from C6
cells overexpressing DDAH had a greater tumor vascular
development and blood volume compared to wild type, and
this was confirmed by subsequent histologic analysis [26].
Overexpression of DDAH also increased both the expression
and secretion of VEGF [24].
In this study, we have taken advantage of this murine
tumor model system expressing a well-defined and charac-
terized phenotypic difference in angiogenesis [24,26], and
assessed the oxygenation status of tumors derived from both
C6 cells overexpressing DDAH and wild-type cells in vivo,
using a variety of direct and indirect methods of measuring
hypoxia. Specifically, we used: 1) immunohistochemical
analysis of the 2-nitroimidazole hypoxia marker pimonida-
zole [27,28]; 2) the OxyLite/OxyFlo system, which directly
measures tumor pO2 and erythrocyte flow [29–32]; and 3)
31P magnetic resonance spectroscopy (MRS) from which
information about the tumor bioenergetic state and pH can
be derived and used as a surrogate marker of hypoxia
[33,34]. Tumor extracts were also assessed for glucose,
lactate, adenosine triphosphate (ATP), and phosphate. In
addition, preliminary immunohistochemistry was performed
to investigate the expression of the glucose transporter-1
(Glut-1) protein, which is upregulated by hypoxia and is a
functional marker of HIF-1 activity [35,36]. Taken together,
the data suggest that: 1) constitutive overexpression of
DDAH results in the increase of tumor hypoxia compared
to C6 wild-type gliomas; and 2) at least in this tumor model
system, tumor oxygenation is inversely related to vascular
density in vivo.
Materials and Methods
Animals and Tumors
Clone 27 (D27) C6 glioma cells, transfected with the full
coding region of the rat DDAH I gene, and wild-type C6 cells
were used [24]. Cells (2  106) were injected into the flanks
of female nu/nu mice under halothane anesthesia. Several
cohorts of each tumor type were used and, in each case, the
growth rate was monitored to confirm that the D27 tumors
grew twice as fast as C6 wild-type tumors, as previously
described [24]. For all studies, size-matched D27 and C6
wild-type tumors were used (mean volume ± 1 SEM, 0.79 ±
0.2 cm3). All experiments were performed in accordance
with the UK Home Office Animals (Scientific Procedures)
Act 1986.
Fluorescence Microscopy of Hoechst 33342 Uptake and
Pimonidazole Immunohistochemistry
Tumor perfusion was assessed by the uptake of the
perfusion marker Hoechst 33342 (Sigma, Poole, UK) [26].
Tumor hypoxia was assessed using an immunohistochem-
ical approach following administration of pimonidazole hy-
drochloride (Hypoxyprobe; Natural Pharmacia International,
Research Triangle Park, NC) [27]. Pimonidazole is a
2-nitroimidazole bioreductive chemical probe with an im-
munorecognizable side chain. Nitroimidazoles undergo a
hypoxia-dependent, one-electron reduction catalyzed by
cellular reductases, resulting in reactive intermediates that
form adducts with cellular components at pO2 tensions of
typically 10 mm Hg or less [27]. Subsequent detection of
these adducts by immunohistochemistry can thus give a
qualitative assessment of tissue hypoxia.
Mice were administered pimonidazole (60 mg/kg, i.p.).
Forty-fiveminutes later, themice were administered 15mg/kg
Hoechst 33342 through a lateral tail vein. One minute later,
the mice were killed by cervical dislocation and the tumors
rapidly excised, frozen, and stored in liquid nitrogen. Serial
sections (10 mm) were cut on a cryotome and stored
at 80jC until processed. Sections were fixed in ice-cold
acetone for 10 minutes and then mounted in phosphate-
buffered saline (PBS). Hoechst 33342 fluorescence signals
from whole tumor sections were then recorded at 365 nm
using a motorized scanning stage (Prior Scientific Instru-
ments Ltd., Cambridge, UK) attached to a BX51 microscope
(Olympus Optical Co. Ltd, London, UK), driven by analySIS
(Soft Imaging System, Munster, Germany). Digital images
from both C6 and D27 tumors were acquired using the same
exposure time and composite images then synthesized.
Fluorescent particles were detected above a threshold that
was constant for all the composite images, and the area of
the tumor section with Hoechst 33342 fluorescence deter-
mined and expressed as a percentage of the whole tumor
section (mean Hoechst-perfused area, mHPA). As the
images were acquired and analyzed under identical condi-
tions, any differences in mHPA would result from differ-
ences in tumor perfusion.
For pimonidazole staining, the same sections were then
incubated first with 2% BSA (wt/vol)/5% goat serum (vol/vol)
for 30 minutes, and then with Hypoxyprobe-1 monoclonal
antibody (1:10 dilution) (Natural Pharmacia International) for
1 hour at room temperature. Following extensive washing
with PBS/0.1% (vol/vol) Tween-20, the sections were then
incubated with biotinylated anti–mouse immunoglobulins
(1:100 dilution) for 1 hour at room temperature, washed in
PBS/0.1% (vol/vol) Tween-20, and incubated with fluores-
cein streptavidin (1:100 dilution) in the dark for 30 minutes.
Regions of pimonidazole adduct formation were detected at
450 to 490 nm using the same fluorescence microscope
system, and composite images of whole tumor sections were
recorded from the identical stage coordinates, allowing the
pimonidazole images to be subsequently overlaid on the
Hoechst 33342 images. As for Hoechst 33342, fluorescent
particles were detected above a constant threshold, and
the area of the tumor section with pimonidazole adduct
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fluorescence was determined and expressed as a percent-
age of the whole tumor section (mean pimonidazole adduct
area, mPAA). As the images were acquired and analyzed
under identical conditions, any differences in mPAA would
result from differences in tumor hypoxia.
OxyLite/OxyFlo Measurements
Mice were anesthesized with a 10-ml/kg intraperitoneal
injection of fentanyl citrate (0.315 mg/ml) plus fluanisone
(10 mg/ml) (‘‘Hypnorm’’; Janssen Pharmaceutical Ltd., High
Wycombe, UK), midazolam (5 mg/ml) (‘‘Hypnovel’’; Roche,
Welwyn Garden City, UK), and water (1:1:2). Tumor pO2
(mm Hg) was measured using the recently developed fiber
optic oxygen-sensing device OxyLite (Oxford Optronix,
Oxford, UK). The pO2 measurements are based on the prin-
ciple that, following optical excitation of a ruthenium
luminophor at the fiber tip, the half-life to return to the ground
state is inversely related to the oxygen tension [37]. Precali-
brated probes supplied by the manufacturer were used
because the response of the sensor to pO2 is nonlinear. In
addition, as the luminescence lifetime is temperature-depen-
dent, pO2 measurements were corrected automatically for
differences in temperature, measured by a thermocouple
attached to the OxyLite probe. Coupled to some of the Oxy-
Lite probes were laser Doppler OxyFlo probes, which mea-
sure erythrocyte flux and hence changes in tumor perfusion
at a similar location.
Up to three probes were introduced into each tumor. Each
probe was inserted deep into the tumor and then retracted
back to sample the tissue pO2 at five different locations per
track. Measurements were made for a minimum of 5 minutes
at each location, which was sufficient to allow the sensor to
equilibrate to the local oxygen tension prior to obtaining a
stable reading for each location. For some locations, the data
were rejected as the probe was unable to equilibrate. Data
acquisition and averaging were done using Chart version 4
(AD Instruments, Castle Hill, Australia).
31P MRS
For 31P MRS, 1.2 g/kg of the extracellular pH marker
3-aminopropylphosphonate (3-APP) in PBS was injected in-
traperitoneally about 20minutes prior to data acquisition [38].
Anesthesized mice were placed in the bore of a 4.7-T
horizontal magnet fitted with a 10-G/cm, 12-cm bore high-
performance auxiliary gradient insert, interfaced to a Varian
UnityInova spectrometer (Varian Inc., Palo Alto, CA), so that
the tumors hung into a two-turn 31P surface coil of 10 mm
diameter. Body temperature wasmaintained at ca. 37jCwith
a water-heated pad placed over the mouse. Field homoge-
neity was optimized by shimming on the water signal for each
tumor to a linewidth, typically, of 30 to 50 Hz. The position of
the tumor was determined by 1H scout images.
Localized 31P MR spectra were acquired from cuboidal
volumes using a modified version of the image-selected
in vivo spectroscopy (ISIS) technique [39] to minimize signal
contamination from underlying tissues. The voxel was se-
lected to exclude nontumor tissue, although in some instan-
ces, overlying skin was included. Slice selection employed
adiabatic (sin cos) inversion pulses with a gradient strength
of 7.5 G/cm. Acquisition employed a hard 90j pulse and
a spectral width of 5 kHz with a pulse repetition time of
3 seconds. Because extracellular pH measurements were
being made, a double ISIS approach, which produces two
spectra (one centered on 3-APP and one centered on
a-NTP), was used to minimize the chemical shift artifact
introduced due to the wide chemical shift range between
3-APP and a-NTP [40]. Total acquisition time was 52minutes
and 512 transients were averaged for each free induction
decay.
Spectral analysis was performed by the variable projec-
tion method (VARPRO) time domain nonlinear least squares
method, yielding the following peak parameters: areas,
frequencies, linewidths, and phases [41]. For each VARPRO
analysis, the first four data points were excluded from the
fit to eliminate the fast-decaying signals from immobilized
phosphates, which cause a baseline hump in the spectra.
The data were fitted by assuming contributions from phos-
phomonoesters (PMEs), inorganic phosphate (Pi), phospho-
diesters (PDEs; when visible), phosphocreatine (PCr), and
three nucleoside triphosphate (NTP) resonances, and peaks
were assumed to be single Lorentzians. The only biochem-
ical and experimental prior knowledge used was that all
peaks were assumed to have a phase equal to the overall
zero-order phase of the spectrum. In the process of nutri-
tional deprivation as occurs with tumor growth, NTP
decreases and Pi increases, so the ratio of ‘‘high-energy’’
to ‘‘low-energy’’ phosphates is used as a measure of the
bioenergetic state. The PME resonance primarily consists of
the phospholipid metabolites phosphocholine and phos-
phoethanolamine associated with membrane biosynthesis,
and is thus used as an index of proliferation. Relative peak
area ratios of the observed phosphates (e.g., bNTP/Pi,
Pi/SP, and PME/SP) were thus determined from the spec-
trum centered on a-NTP. SP was taken to be the sum of all
peaks fitted by VARPRO analysis. Intracellular tumor pHi
was determined by using the VARPRO-derived frequen-
cies for the Pi and a-NTP resonances from the spectrum
centered on a-NTP, whereas the extracellular pH was de-
termined using the VARPRO-derived frequency for 3-APP
from the spectrum centered on 3-APP.
Tissue Metabolites
Tumors were rapidly excised and freeze-clamped with
liquid nitrogen–cooled tongs, followed by extraction with 6%
perchloric acid and neutralization. Tissue glucose, lactate,
and ATP were measured on the neutralized extracts accord-
ing to Bergmeyer [42], and phosphate was measured
according to ChandraRajan and Klein [43].
Glut-1 Immunohistochemistry
For Glut-1 analysis, C6 (six sections from three separate
tumors) and D27 (five sections from three separate tumors)
tumor sections were incubated overnight at 4jC in the pres-
ence of Glut-1 primary antibody (affinity-pure rabbit anti–rat
Glut-1; Alpha Diagnostic International, San Antonio, TX) at a
dilution of 1:100. Control sections were incubated with rabbit
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IgG (1:100). Secondary antibody treatment (biotinylated an-
ti–rabbit IgG diluted 1:300) and visualization of immunoreac-
tivity with DAB were facilitated by using the Vector ABC kit
(Vector Laboratories, Peterborough, UK). The sections were
then washed, dehydrated, and mounted. Composite images
of whole tumor sections and high-power images were then
recorded as described above. A blind semiquantitative anal-
ysis was performed using a scale of 0, 1, 2, or 3 to score each
section according to the degree of Glut-1 staining observed.
Statistical Analyses
Results are presented in the form mean ± 1 SEM.
Significance testing employed the two-tailed Student’s t test
with a 5% confidence level.
Results
Fluorescent composite images of histologic sections
obtained from D27 and C6 wild-type tumors stained for the
perfusion marker Hoechst 33342 (blue) and reduced adducts
of the 2-nitroimidazole hypoxia marker pimonidazole (green)
are shown in Figure 1. Both tumor types showed a hetero-
geneous pattern of distribution of Hoechst 33342 and pimo-
nidazole adduct formation. A greater abundance of Hoechst
33342 staining was associated with the D27 tumors, and the
mHPA of the D27 tumors (13.2 ± 2%, n = 3, three sections
per tumor) was significantly greater than C6 wild-type
(7.8 ± 1%, n = 3, three sections per tumor, P < .02, Student’s
t-test). A greater extent of pimonidazole adduct formation
was seen in the D27 tumors (mPAA, 14.1 ± 3%) compared
to C6 wild type (mPAA, 11.6 ± 1%), consistent with the
greater abundance of reduced cellular intermediates and
hence increased tissue hypoxia.
Traces obtained from an OxyLite pO2 probe (coupled with
an OxyFlo Laser Doppler Flowmetry [LDF] probe), inserted
into a C6 wild-type glioma and subsequently retracted back
through the tumor at five locations as indicated, are shown in
Figure 2. The spikes in the LDF trace clearly mark the time of
movement of the probe to a new location. There was no trend
toward decreasing pO2 measurements as the probe was
retracted through the tumor, suggesting that initial insertion
of the probe into the tumor did not induce local hypoxia
Figure 1. Composite images of tissue sections obtained from C6 wild type and D27 tumors stained for the perfusion marker Hoechst 33342 and the
2-nitroimidazole hypoxia marker pimonidazole. Tumor blood vessels perfused at the time of injection of Hoechst 33342 appear blue, and regions of pimonidazole
adducts fluoresce green by means of biotinylated goat anti –mouse IgG second antibody and fluorescein streptavidin detection. Qualitatively, the D27 tumors
exhibited a greater extent of both Hoechst 33342 and pimonidazole staining compared to C6 wild type, consistent with the greater abundance of both perfused
blood vessels and increased tissue hypoxia.
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through the track. Rather, wide fluctuations were measured
in pO2 at all locations. Note also how relatively high pO2 was
matched with an increase in noise of the LDF trace at lo-
cations 2 and 3, suggesting that the probe tips were either
within, or proximal to, an area of hemodynamic activity at
these locations. The pO2 measurements were collated as
frequency histograms from which the mean and median
pO2, and the percentage of values less than 2.5 mm Hg
(considered representative of radiobiologic hypoxia) were
determined (Figure 3). The data clearly show that the D27
tumors were significantly more hypoxic than the C6 wild-
type gliomas.
Representative localized 31P MR spectra obtained from
one D27 and one C6 wild-type tumor are shown in Figure 4.
Resonances were typically identified for the 3-APP, PME, Pi,
PDE, PCr, g-NTP, a-NTP, and b-NTP resonances. The
spectra shown in Figure 4 were those centered on the
a-NTP resonance, hence the poor appearance/phasing of
the 3-APP peak. A PDE resonance was clearly resolved in
all the C6 wild-type gliomas, but discernible in only one
D27 tumor. The 31P MRS results are summarized in
Table 1, which show that, compared to C6 wild type, the
D27 tumors exhibited a significantly lower bioenergetic state,
reflected by the bNTP/Pi and Pi/SP ratios, coupled with a
more acidic intracellular and extracellular pH. The PME/SP
ratio, an index of proliferation, was also greater in the D27
tumors compared to C6 wild type but was not statistically
significant.
Tissue metabolites were measured enzymatically in
extracts of C6 and D27 tumors, and the results are shown
in Table 2. Significantly lower concentrations of glucose were
measured in the D27 tumors compared to C6 wild type,
whereas there was no significant difference between the
concentrations of lactate, ATP, or phosphate.
Immunohistochemically stained tumor sections for Glut-1
protein are shown in Figure 5. Glut-1 staining was observed
in both tumor types. However, in the sections obtained from
D27 tumors, Glut-1 staining was clearly more abundant,
whereas in the C6 sections, Glut-1 staining wasmore diffuse.
No Glut-1 staining was apparent in equivalent regions of the
control slides (not shown). Accordingly, the semiquantitative
analysis of Glut-1 staining revealed a median score of 1 for
the C6 sections, whereas a median score of 3 was deter-
mined for the sections obtained from D27 tumors.
Discussion
The induction of tumor hypoxia has often been linked to
rapidly proliferating tissue outgrowing its nutritive blood
supply. Recent clinical data have shown correlates of high
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Figure 2. Traces obtained from (a) one OxyLite pO2 probe, coupled with (b) an OxyFlo LDF probe, from a C6 wild-type glioma. The probe was inserted into the
tumor and then with time retracted back through the tumor to measure the pO2 at five locations as indicated. The intense spikes in the LDF trace clearly mark the
time of movement of the probe.
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vascular density with both necrosis and poor radiotherapeu-
tic/chemotherapeutic outcome, suggesting the paradox of
increasing hypoxia correlating with high vascular density.
As an approach to investigate the relationship of angiogen-
esis and hypoxia, we have taken advantage of a tumor
system expressing a well-defined phenotypic difference in
angiogenesis through overexpression of DDAH [24,26], and
assessed the oxygenation status of these tumors with an
array of direct and indirect assays of hypoxia in vivo.
The degree of perfusion and hypoxia of wild-type C6 and
D27 tumors was assessed by Hoechst 33342 uptake and
immunohistochemical detection of reduced adducts of pimo-
nidazole respectively. Tumor uptake of Hoechst 33342 was
similar to our previous measurements and again showed
a significant increase in the D27 tumors overexpressing
DDAH, consistent with increased perfusion [24,26]. The
addition of the first electron in the bioreductive activation of
pimonidazole is reversibly inhibited by O2, with half maximal
pO2 of inhibition of about 3 mm Hg and complete inhibition
at approximately 10 mm Hg [27]. Using pimonidazole affords
a distribution pattern of hypoxic regions throughout a whole
tissue section. Pimonidazole adduct formation was evident
in both C6 and D27 tumors, similar to that observed in E106
gliomas [30]. However, the D27 tumors clearly showed a
greater extent of adduct formation, consistent with their
being more hypoxic.
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Figure 3. Frequency histograms of the pO2 measurements obtained from (a) clone D27 and (b) C6 wild-type tumors. N is the number of tumors studied and n is the
total number of individual pO2 measurements made and used for the data analyses. Results are shown for the mean ± 1 SEM and median pO2 (in mm Hg), and
also the percentage of values less than 2.5 mm Hg, considered indicative of radiobiological hypoxia (**P < .002). The data are consistent with the D27 tumors being
significantly more hypoxic.
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Tumor pO2 was measured with fiber optic oxygen-sens-
ing OxyLite probes. One advantage of this approach over
other oxygen electrodes is that no oxygen itself is consumed
during the measurement process, thus allowing the probe
to be left at any one location indefinitely. Furthermore, the
signal-to-noise ratio increases with decreasing pO2, thus
making the OxyLite sensor accurate at measuring the low
oxygen tensions typically experienced within tumors [37].
The mean pO2 of the C6 wild-type gliomas was 7.1 mm Hg.
This is lower than the mean pO2 of two other glioblastoma
xenografts—the E102 (24 mm Hg) and E106 (18.5 mm Hg)
—but greater than the squamous cell xenograft SCCNij3
(4.9 mm Hg) and sarcoma F (2.8 mm Hg), all measured by
the OxyLite [30,31]. The mean pO2 of the D27 tumors, which
grow more rapidly and are more vascularized than C6 wild
type [24,26], was significantly lower (3.2 mm Hg), consistent
with the concept of an inverse relationship between vas-
cular density and pO2. A similar relationship has also
been reported in the clinic. Oxygen measurements of hu-
man gliomas with the Eppendorf pO2 histograph demon-
strated significant proportions of hypoxia in glioblastoma [44]
and also a small, nonsignificant difference between low-
grade and high-grade tumors, with the latter being more
hypoxic [45].
Localized 31P MRS, which reports on tumor bioenergetic
status and pH, was used to assess the metabolic conse-
quences of hypoxia. Although changes in levels of NTP
and Pi cannot strictly be interpreted as changes in tumor
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Figure 4. Representative ISIS-localized 31P MR spectra obtained from (a) one D27 and (b) one C6 tumor. Resonance assignments are: 3-APP,
3-aminopropylphosphonate; PMEs, phosphomonoesters; Pi, inorganic phosphate; PDEs, phosphodiesters; PCr, phosphocreatine; c-NTP, a-NTP, and -NTP,
nucleoside triphosphate. The spectra shown are those centered on the a-NTP resonance, hence the poor appearance/phasing of the 3-APP peak.
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oxygenation, a more hypoxic tumor would be expected to
show depleted high-energy phosphates and increased Pi,
coupled with a decline in pH [33]. The bioenergetic status of
the D27 gliomas, assessed from the bNTP/Pi and Pi/SP
ratios determined from the 31P MR spectra, was significantly
reduced compared to the C6 wild type, again consistent with
the more aggressive tumors being more hypoxic.
The measured pHi and pHe of the wild-type C6 gliomas
were similar to those previously reported [46,47]. The C6
gliomas exhibited the reversed transmembrane pH gradient
typical of tumors, with the intracellular pH being maintained
at, or greater than, neutrality, whereas the extracellular pH is
more acidic [48]. In the D27 tumors, both the intracellular and
extracellular pH values were more acidic and no gradient
was apparent. The ATP-dependent Na+/K+ antiport, which is
activated in transformed cells, is one of the key routes used
by tumor cells to export protons out into the extracellular
space [48]. A recent study showed that this antiport can be
nitrosylated by endogenous NO [49]. Elevated NO levels, a
consequence of overexpression of DDAH I, may thus impair
the function of the ATP-dependent Na+/K+ antiport, resulting
in a buildup of protons and a lowering of the intracellular pH,
eliminating the usual transmembrane pH gradient.
The PME resonance contains contributions primarily from
phosphocholine and phosphoethanolamine, phospholipids
associated with membrane biosynthesis [34], so the greater
PME/SP ratio of the D27 tumors compared to wild type
reflects the enhanced proliferation rate of these tumors.
This, coupled with the observation of a PDE resonance in
all the C6 wild-type tumors but not in the more aggressive
D27 tumors, is also consistent with a glycerophosphocho-
line-to-phosphocholine switch, previously shown to be asso-
ciated with malignant transformation and progression [50].
It has previously been shown that C6 gliomas preferen-
tially use glycolysis for energy production, even in the
presence of adequate oxygen concentrations [51]. The de-
termination of tissue glucose, lactate, ATP, and Pi concen-
trations gives useful information about the steady-state
tumor metabolism, which can be related to the oxygenation
status of the tumor, but does not inform directly on metabol-
ic rates. Metabolite assays showed a significantly lower
concentration of tissue glucose in the D27 gliomas compared
to C6 wild type. This is consistent with a higher glucose
uptake by the D27 cells and hence a faster metabolic rate.
We have previously reported an increased blood volume in
the D27 gliomas compared to wild type [26]. A high micro-
vascular blood volume, measured by susceptibility contrast
MRI, has been shown to be associated with high glucose
uptake, measured by FDG-PET, and tumor angiogenesis in
human gliomas [52]. Despite the difference in tissue glucose
concentration, there were no significant differences in tissue
lactate (the end-product of anaerobic glycolysis), ATP, or Pi
concentrations between the two tumor types. Similar lactate
concentrations have been measured in C6 gliomas
implanted in the rat brain, and lactate has also been shown
to be actively turning over, consistent with a predominantly
glycolytic metabolism [53,54]. The steady-state tumor ex-
tract and 31P MRS measurements, coupled with the en-
hanced growth rate and blood volume [24,26], are
consistent with the enhanced hypoxia in the D27 tumors
overexpressing DDAH as a consequence of an increased
metabolic rate rather than a limited substrate (glucose)
supply. It is likely that kinetic studies would reveal a differ-
ence in glycolytic rates, and studies using in vivo 13C MRS
of D27 and C6 tumors following the infusion of I[13C]-labelled
glucose are currently being pursued to address this [55].
Glut-1, which is induced by hypoxia, has been shown to
be a reliable functional marker for HIF-1–mediated meta-
bolic adaptation in HIF-1–deficient tumors [35]. Further-
more, clinical evidence suggests that Glut-1 expression is
associated with an aggressive phenotype and has prognos-
tic potential [36]. We hypothesized that the measured reduc-
tion in glucose concentration in tissue extracts of the D27
tumors may reflect an increase in the expression of glucose
transporters through the HIF-1 pathway. Preliminary immu-
nohistochemical studies clearly demonstrated increased fo-
cal Glut-1 expression in D27 tumors compared to wild-type
Table 1. Summary of the Localized 31P MRS Data from C6 Wild Type and Clone D27 Tumors.
Tumor N NTP/PI Pi/SP pHi pHe PME/SP
C6 6 1.9 ± 0.2 0.11 ± 0.01 7.18 ± 0.02 7.10 ± 0.02* 0.14 ± 0.02
D27 6 0.96 ± 0.11y 0.18 ± 0.02y 6.97 ± 0.04y 6.99 ± 0.04z 0.2 ± 0.01§
N is the number of tumors studied. Results are mean ± 1 SEM. The data are consistent with the D27 tumors having a significantly poorer bioenergetic status,
indicated by the significantly lower NTP/Pi ratio and significantly higher Pi/SP ratio. The extracellular pH (pHe) of the C6 gliomas was significantly more acidic than
the intracellular pH (pHi), giving rise to a classic reversed pH gradient. However, in the D27 tumors, there was no significant difference between pHi and pHe
(P > .1). Both pHi and pHe were significantly more acidic compared to C6 wild type. The PME/SP ratio, an indicator of tissue proliferation, was elevated in the D27
tumors compared to C6 wild type but was not statistically significant.
*P < .02.
yP < .002.
zP < .03.
§P = .06.
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Table 2. Summary of the Tissue Metabolite Concentrations (mol/g wet wt)
Measured Enzymatically from Extracts of C6 Wild Type and Clone D27
Tumors.
Tumor N Glucose Lactate ATP Phosphate
C6 5 2.54 ± 0.2 7.38 ± 0.8 0.77 ± 0.1 6.59 ± 0.8
D27 5 1.41 ± 0.2* 7.44 ± 0.4 0.75 ± 0.1 5.56 ± 1.1
N is the number of tumors studied. Results are mean ± 1 SEM. Significantly
lower concentrations of glucose were measured in the D27 tumors.
*P < .01.
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C6, supporting a role for the HIF-1 pathway in the adaptation
of the D27 tumors to hypoxic stress.
Taken together, the data point toward an inverse relation-
ship of tumor oxygenation and angiogenesis in vivo in this
tumor system, supporting the hypothesis that increased
tumor hypoxia stimulates tumor angiogenesis. We have
previously shown that overexpression of DDAH in D27
tumors under normoxic conditions results in an increase in
expression and secretion of VEGF compared to wild-type C6
gliomas [24]. This results in the enhancement of tumor blood
vessel development, blood volume, and perfused blood
vessels in the D27 tumors [24,26], and is consistent with
HIF-1– induced VEGF being a survival factor secreted by the
tumor cells in response to hypoxic stress.
In summary, we have shown that overexpression of
DDAH in C6 gliomas, which we have previously shown to
give a more aggressive and better-vascularized phenotype,
causes them to be more hypoxic compared to C6 wild-type
tumors in vivo. The data point strongly to an inverse rela-
tionship between tumor oxygenation and angiogenesis
in vivo, consistent with several recent clinical observations,
and is a concept in accordance with the enhanced under-
standing of oxygen sensing at the molecular level.
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